Please assess the completion status of the following clinical trial:

Trial Title: The Safety and Efficacy of Intralymphatic Immunotherapy in Pollen Allergic Adolescents and Young Adults With Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Allergic rhinitis due to grass or birch pollen~* Mild to moderate asthma with a positive methacholine challenge~* Accepted and signed informed consent.~Exclusion Criteria:~* Previously subcutaneous immunotherapy (SCIT) with total symptom relief.~* Previously SCIT but no symptom improvement at all.~* Sensitizations to house dust mite or furry animals, with ongoing exposure and symptoms.~* Severe atopic dermatitis.~* Patients with significant diseases other than allergic rhinitis. A significant disease is defined as a disease which in the opinion of the investigator may either put the patient at risk because of participation in the study or a disease which may influence the results of the study or the patient's ability to participate in the study.~* Patients with a respiratory tract infection in the past 4 weeks prior to Visit 2.~* Pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception (i.e., oral contraceptives, intrauterine devices, diaphragm, or subdermal implants).~* Known autoimmune or collagen disease~* Cardiovascular disease~* Hepatic disease~* Known renal insufficiency~* Cancer~* Hematologic disease~* Chronic infectious disease~* Any medication with a possible side-effect of interfering with the immune response~* Previous immuno- or chemotherapy~* Disease or conditions rendering the treatment of anaphylactic reactions difficult (symptomatic coronary heart diseases, severe arterial hypertension and treatment with β-blockers)~* Major metabolic disease~* Known or suspected allergy to the study product~* Obesity with BMI \> 30 since subcutaneous fat makes ultrasound imaging of lymph nodes harder which may risk the correct placement of injection.~* Patients who, in the opinion of the investigator, abuse alcohol or drugs within 2 years prior to Visit 1.~* Patients who have taken an investigational drug within 1 month or six half lives, whichever is greater, prior to Visit 1.~* Mental incapability of coping with the study~* Withdrawal of informed consent

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): ALK diluent 0,3% human albumin'
- Active treatment (Type: EXPERIMENTAL): Intervention: Drug ALK Alutard birch or 5-grasses. Grass pollen suspension or birch pollen suspension

Based on this trial design, predict the completion outcome and termination type (if applicable).